| Public | TSX:MDG |
| Website | medicago.com |
| Category | BioTech |
| Phone | 418 658.9393 |
| Employees | |
| Founded | 1997 |
| TOTAL | $10M |
| VENTURE FUNDING TOTAL | $10M |
| Venture Round, 5/10 Yorkville Advisors | $10M |
Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.
